ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $494,794 | -0.5% | 5,284 | -5.1% | 0.01% | +14.3% |
| Q2 2023 | $497,123 | -19.9% | 5,570 | -3.7% | 0.01% | -30.0% |
| Q1 2023 | $620,482 | -13.7% | 5,787 | -1.7% | 0.01% | -16.7% |
| Q4 2022 | $719,346 | -6.8% | 5,890 | -21.2% | 0.01% | -14.3% |
| Q3 2022 | $772,000 | +7.1% | 7,476 | -3.6% | 0.01% | +16.7% |
| Q2 2022 | $721,000 | -45.9% | 7,757 | -31.7% | 0.01% | -36.8% |
| Q1 2022 | $1,333,000 | -17.9% | 11,359 | -5.9% | 0.02% | -13.6% |
| Q4 2021 | $1,624,000 | -22.8% | 12,074 | -8.5% | 0.02% | -26.7% |
| Q3 2021 | $2,103,000 | +55.5% | 13,195 | +28.4% | 0.03% | +57.9% |
| Q2 2021 | $1,352,000 | +34.1% | 10,277 | +31.4% | 0.02% | +18.8% |
| Q1 2021 | $1,008,000 | +34.8% | 7,823 | +74.5% | 0.02% | +33.3% |
| Q4 2020 | $748,000 | +106.1% | 4,484 | +90.7% | 0.01% | +71.4% |
| Q3 2020 | $363,000 | +81.5% | 2,351 | +73.5% | 0.01% | +75.0% |
| Q2 2020 | $200,000 | +308.2% | 1,355 | +210.1% | 0.00% | +300.0% |
| Q1 2020 | $49,000 | – | 437 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |